Previous analyses of this patient population showed that patients whose cancers had low proliferation rates based on central Ki67 assessment had low recurrence rates and were less likely to benefit from the addition of capecitabine.20 Here we sought to use molecular analyses to more precisely define the high- and low-risk patients within this study population. This evidence concerns the gene MKI67 and cancer.